Cover Image

Evaluation of the symptomatic treatment of residual neurological symptoms in Wilson disease

The intention of this analysis was to identify patients with treated Wilson disease (WD) and residual neurological symptoms in order to determine whether or not they were undergoing any treatment in addition to the common decoppering medication. Moreover, the effects of any symptomatic medication we...

Full description

Saved in:
Bibliographic Details
Main Authors: Hölscher, Sara (Author) , Leinweber, Barbara (Author) , Hefter, Harald (Author) , Reuner, Ulrike (Author) , Günther, Peter (Author) , Weiss, Karl Heinz (Author) , Oertel, Wolfgang H. (Author) , Möller, Jens Carsten (Author)
Format: Article (Journal)
Language:English
Published: August 2010
In: European neurology
Year: 2010, Volume: 64, Issue: 2, Pages: 83-87
ISSN:1421-9913
DOI:10.1159/000316066
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000316066
Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/316066
Get full text
Author Notes:Sara Hölscher, Barbara Leinweber, Harald Hefter, Ulrike Reuner, Peter Günther, Karl Heinz Weiss, Wolfgang H. Oertel, Jens Carsten Möller
Description
Summary:The intention of this analysis was to identify patients with treated Wilson disease (WD) and residual neurological symptoms in order to determine whether or not they were undergoing any treatment in addition to the common decoppering medication. Moreover, the effects of any symptomatic medication were analyzed. Two samples of WD patients were investigated either by a mailed questionnaire survey (n = 135) or by a retrospective analysis (n = 75). A considerable proportion of patients still suffered from neurological symptoms (n = 106, 50.5%), of whom a relatively small proportion was treated symptomatically (n = 33, 31.1%). The documented effects varied substantially, with anticholinergics and botulinum toxin (against dystonia) and primidone (against tremor) apparently being the most promising compounds. Further studies are required to analyze the symptomatic treatment of WD patients with residual neurological symptoms in more detail.
Item Description:Gesehen am 06.03.2023
Physical Description:Online Resource
ISSN:1421-9913
DOI:10.1159/000316066

Similar Items